Soleno Therapeutics Inc (SLNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has a cash flow conversion efficiency ratio of 0.052x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.98 Million) by net assets ($495.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SLNO stock market capitalisation for the company's overall valuation and market capitalisation.
Soleno Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Soleno Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soleno Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Soleno Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Marzetti Company
NASDAQ:MZTI
|
0.055x |
|
Brookdale Senior Living Inc
NYSE:BKD
|
-0.383x |
|
Inversiones la Construccion S.A.
SN:ILC
|
-0.023x |
|
Vapores
SN:VAPORES
|
-0.073x |
|
Xiamen Intretech Inc Class A
SHE:002925
|
0.019x |
|
Redwire Corp
NYSE:RDW
|
-0.019x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
|
Digi International Inc
NASDAQ:DGII
|
0.161x |
Annual Cash Flow Conversion Efficiency for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Soleno Therapeutics Inc from 2012 to 2025. View Soleno Therapeutics Inc (SLNO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $450.12 Million | $46.80 Million | 0.104x | +136.88% |
| 2024-12-31 | $245.11 Million | $-69.10 Million | -0.282x | -78.03% |
| 2023-12-31 | $157.51 Million | $-24.94 Million | -0.158x | +92.12% |
| 2022-12-31 | $10.35 Million | $-20.78 Million | -2.008x | -28.67% |
| 2021-12-31 | $17.79 Million | $-27.77 Million | -1.561x | -181.82% |
| 2020-12-31 | $45.55 Million | $-25.22 Million | -0.554x | +52.36% |
| 2019-12-31 | $14.95 Million | $-17.38 Million | -1.162x | -202.60% |
| 2018-12-31 | $30.41 Million | $-11.68 Million | -0.384x | -2.45% |
| 2017-12-31 | $26.53 Million | $-9.95 Million | -0.375x | +90.46% |
| 2016-12-31 | $3.44 Million | $-13.50 Million | -3.929x | -22.99% |
| 2015-12-31 | $3.22 Million | $-10.30 Million | -3.195x | -836.12% |
| 2014-12-31 | $-10.33 Million | $-4.48 Million | 0.434x | +1756.41% |
| 2013-12-31 | $-37.86 Million | $-885.22K | 0.023x | -77.14% |
| 2012-12-31 | $-34.20 Million | $-3.50 Million | 0.102x | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more